Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Weiss, Andrea ^a,b   Bonvin, Débora ^a   Berndsen, Robert H ^a,b   Scherrer, Edoardo ^a   Wong, Tse J ^b   Dyson, Paul J ^a   Griffioen, Arjan W ^b   Nowak Sliwinska, Patrycja ^a,b  

^a EPFL   (Switzerland)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; DICHLORO(4-CYMENE)(1,3,5-TRIAZA-7-PHOSPHATRICYCLO(3.3.1.1)DECANE)RUTHENIUM(II); DOXORUBICIN; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ORGANOMETALLIC COMPOUND; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; SUNITINIB;

ANIMAL; CHICK EMBRYO; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN CONSUMPTION; PATHOLOGY; PHOTOCHEMOTHERAPY; TUMOR CELL LINE; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHICK EMBRYO; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG SYNERGISM; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; OXYGEN CONSUMPTION; PHOTOCHEMOTHERAPY; PROTEIN KINASE INHIBITORS; PYRROLES; TUMOR BURDEN;

EID: 84924777867     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08990     Document Type: Article

References (54)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1, 27-31 (1995).
2. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
3. Griffioen, A. W. & Molema, G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 52, 237-268 (2000).
4. Jain, R. K. & Baxter, L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48, 7022-7032 (1988).
5. Nagy, J. A., Chang, S. H., Dvorak, A. M. & Dvorak, H. F. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 100, 865-869 (2009).
6. Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 64, 353-365 (2012).
7. Brown, J. M. Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy. Br J Radiol. 87, 20130686 (2014).
8. Agostinis, P. et al. Photodynamic therapy of cancer: an update. CA: Cancer J Clin. 61, 250-281 (2011).
9. Cosse, J. P. & Michiels, C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem. 8, 790-797 (2008).
10. Perentes, J. Y. et al. Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model. Transl Oncol. doi:10.1016/ j.tranon.2014.04.010 (2014).
11. Kato, M., Hattori, Y., Kubo, M. & Maitani, Y. Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex. Int J Pharm. 423, 428-434 (2012).
12. Chauhan, V. P. et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol. 7, 383-388 (2012).
13. Dings, R. P. et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13, 3395-3402 (2007).
14. Fan, Y. et al. The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin. Biomaterials 34, 2277-2288 (2013).
15. Chen, B. et al. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin Cancer Res 12, 917-923 (2006).
16. de Freitas, L. M., Soares, C. P. & Fontana, C. R. Synergistic effect of photodynamic therapy and cisplatin: A novel approach for cervical cancer. J Photochem Photobiol. B, Biology. 140, 365-373 (2014).
17. Verma, S., Watt, G. M., Mai, Z.&Hasan, T. Strategies for enhanced photodynamic therapy effects. Photochem Photobiol. 83, 996-1005 (2007).
18. Rizvi, I. et al. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res. 70, 9319-9328 (2010).
19. Dings, R. P. et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 13, 3395-3402 (2007).
20. Jain, R. K. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science 307, 58-62 (2005).
21. Jain, R. K. The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation 4, 1-23 (1997).
22. Nowak-Sliwinska, P., Wagnieres, G., van den Bergh, H. & Griffioen, A. W. Angiostasis-induced vascular normalization can improve photodynamic therapy. Cell Mol Life Sci. 67, 1559-1560 (2010).
23. Maity, A. & Bernhard, E. J. Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. Cancer Res. 70, 2141-2145 (2010).
24. Van der Veldt, A. A. et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21, 82-91 (2012).
25. Nowak-Sliwinska, P. et al. Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity. J Med Chem. 54, 3895-3902 (2011).
26. Weiss, A. et al. In vivo anti-tumor activity of the organometallic ruthenium(II)- arene complex [Ru(g6-p-cymene)Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas. Chemical Science 5, 4742-4748 (2014).
27. Bergamo, A., Masi, A., Dyson, P. J. & Sava, G. Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol. 33, 1281-1289 (2008).
28. Shen, F. et al. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther. 324, 95-102 (2008).
29. Goel, S. et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 91, 1071-1121 (2011).
30. Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563 (2004).
31. Matsumoto, S. et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res. 71, 6350-6359 (2011).
32. Eichhorn, M. E. et al. Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment. Cancer Biol Ther. 7, 1006-1013 (2008).
33. Qayum, N. et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res. 69, 6347-6354 (2009).
34. Cerniglia, G. J. et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 4, e6539 (2009).
35. Kirane, A. et al. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res. 18, 5031-5042 (2012).
36. Cham, K. K. et al. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer 103, 52-60 (2010).
37. Liu, J. et al. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res 17, 3638-3648 (2011).
38. Batchelor, T. T. et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 28, 2817-2823 (2010).
39. Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
40. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 10, 145-147 (2004).
41. Fenton, B. M. & Paoni, S. F. The Addition of AG-013736 to Fractionated Radiation Improves Tumor Response without Functionally Normalizing the Tumor Vasculature. Cancer Res. 67, 9921-9928 (2007).
42. Fenton, B. M. & Paoni, S. F. Alterations in Daily Sequencing of Axitinib and Fractionated Radiotherapy do not Affect Tumor Growth Inhibition or Pathophysiological Response. Radiat Res. 171, 606-614 (2009).
43. Ma, J. & Waxman, D. J. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther. 7, 79-89 (2008).
44. Ma, J., Chen, C.-S., Blute, T. & Waxman, D. J. Antiangiogenesis Enhances Intratumoral Drug Retention. Cancer Res. 71, 2675-2685 (2011).
45. Sheikh Ali, M. A. et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci. 99, 1589-1594 (2008).
46. Gottschalk, N., Kimmig, R., Lang, S., Singh, M. & Brandau, S. Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity. Int J Mol Sci. 13, 12000-12016 (2012).
47. Weiss, A. et al. Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J Cell Mol Med. 18, 480-491 (2014).
48. Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 370, 699-708 (2014).
49. Zhuang, H., Zhao, X., Zhao, L., Chang, J. Y. & Wang, P. Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-smallcell lung cancer. Drug Des Dev Ther. 8, 667-675 (2014).
50. Ribatti, D. Vascular normalization: a real benefit? Cancer Chemoth Pharm. 68, 275-278 (2011).
51. Griffioen, A. W. et al. The emerging quest for the optimal angiostatic combination therapy. Biochem. Soc. Trans. 42, 1608-15 (2014).
52. Allardyce, C. S., Dyson, P. J., Ellis, D. J. & Heath, S. L. [Ru(eta(6)-p-cymene)Cl- 2(pta)] (pta 5 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells. Chem Commun 15, 1396-1397 (2001).
53. Lim, S. H. et al. The neovessel occlusion efficacy of 15-hydroxypurpurin-7-lactone dimethyl ester induced with photodynamic therapy. Photochem Photobiol. 86, 397-402 (2010).
54. Adar, Y. et al. Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers. Cell Death Dis. 3, 1-10 (2012).